Europe Continuous Bioprocessing Market to be Worth $206.1 Million by 2030
Meticulous
Research– a leading global market research company, published a research report
titled “Europe Continuous Bioprocessing Market by
Product (Filtration, Chromatography, Centrifuges, Consumables), Application
(Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User
(Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030”.
Download
Free sample Report here: https://www.meticulousresearch.com/product/europe-continuous-bioprocessing-market-5605?utm_source=blog&utm_medium=social+&utm_campaign=product&utm_content=26-02-2024
According
to this latest publication from Meticulous Research, the Europe continuous
bioprocessing market is expected to grow at a CAGR of 19.1% from 2023 to reach
$206.1 million by 2030. The growth of this market is attributed to factors such
as recent product launches and advances in the continuous bioprocessing space,
gradual adoption of continuous manufacturing, and initiatives supporting the
adoption of biopharmaceuticals. Furthermore, the shift towards bioprocessing
4.0 and the rising adoption of personalized medicines are expected to provide
significant market growth opportunities.
However,
the limitations of continuous bioprocessing may restrain the growth of this
market. Additionally, manufacturers’ hesitation to shift from batch
manufacturing to continuous manufacturing poses challenges to the market
players.
Key
Players
The
key players operating in the Europe continuous bioprocessing market are 3M
Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA
(Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG
(Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.),
Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest
(France), and Bionet (U.S.).
Europe
Continuous Bioprocessing Market: Future Outlook
The
Europe continuous bioprocessing market is segmented by Product (Filtration
Systems and Consumables, Chromatography Systems and Consumables, Cell Culture
Media, Buffers, and Reagents, Incubators and Shakers, Bioreactors, Centrifuges,
Sterilizers, and Other Instruments and Consumables), Application (Commercial
Applications [Monoclonal Antibodies (mAbs) Production, Cell and Gene Therapy
Production, Vaccine Manufacturing, Plasma Fractionation, and Recombinant
Protein Production], R&D), End User (Pharmaceutical and Biotechnology
Companies, Contract Development and Manufacturing Organizations (CDMOS) and
Contract Research Organizations (CROS), and Academic and Research Institutes),
and Country. The study also evaluates industry competitors and analyzes the market
at the country level.
In
2023, among the products, the filtration systems
and consumables segment is estimated to account for the largest share of the
market. Filtration is commonly used in biopharmaceutical processing for
separating components. It is used in various downstream operations, such as clarification,
filtration of intermediates, critical final filling applications, or upstream
processing for sterilizing-grade filtration of cell culture media. The highest
revenue share of this segment is attributed to the recurring use of filtration
at every step in bioprocessing and technological advancements in filtration
technologies.
Speak to analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5605?utm_source=blog&utm_medium=social+&utm_campaign=product&utm_content=26-02-2024
In
2023, among the applications, the
commercial applications segment is estimated to account for the largest share
of the market. Growing initiatives supporting the adoption of
biopharmaceuticals, rising biopharmaceutical manufacturing outsourcing, and
accelerated developments in personalized therapies are likely to enhance the
demand for bioprocessing systems and consumables for the commercial
bioproduction of monoclonal antibodies (mAbs), vaccines, gene therapies, and
recombinant protein-based therapies; thereby drive the continuous bioprocessing
market for commercial application.
In
2023, among the end users, the
pharmaceutical and biotechnology companies segment is estimated to account for
the largest market share due to factors such as capacity expansions by
biopharmaceutical manufacturers and the extensive adoption of biopharmaceutical
processing equipment for bioproduction in the biopharmaceutical and
biotechnology sectors.
Geographic
Review
This research report
provides a comprehensive analysis of the continuous bioprocessing market in
Europe (Germany, the U.K., France, Spain, Italy, Switzerland, the Netherlands,
Belgium, Denmark, Ireland, Rest of Europe). In 2023, Germany is expected to account
for the largest share of the Europe continuous bioprocessing market. Factors
such as the increasing vaccination programs, government investment in R&D,
and rising need for biosimilars & personalized medicines supported the
market's growth in Germany.
Quick Buy: https://www.meticulousresearch.com/Checkout/92705191?utm_source=blog&utm_medium=social+&utm_campaign=product&utm_content=26-02-2024
Key
questions answered in the report-
· Which
are the high-growth market segments in terms of product, application, end user,
and country?
· What
was the historical market for continuous bioprocessing across Europe?
· What
are the market forecasts and estimates for the period 2023–2030?
· What
are the major drivers, restraints, opportunities, and challenges in the Europe
continuous bioprocessing market?
· Who
are the major players in the Europe continuous bioprocessing market?
· How
is the competitive landscape, and who are the market leaders in the Europe
continuous bioprocessing market?
· What
are the recent developments in the Europe continuous bioprocessing market?
· What
are the different strategies adopted by the major players in the Europe
continuous bioprocessing market?
· What
are the geographical trends and high-growth countries?
Contact
Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment